Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.40 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085623 | 0.91 | CYP4F2 (0.41) | CYP4F2CYP4A11HPGDMMEL1CYP4Z1 | |
| SCHEMBL2086788 | 0.91 | CYP4F2 (0.41) | CYP4F2CYP4A11HPGDMMEL1CYP4Z1 | |
| SCHEMBL2083156 | 0.88 | HPGD (0.46) | HPGDPTGS2LTB4R2 | |
| SCHEMBL2086756 | 0.88 | HPGD (0.46) | HPGDPTGS2LTB4R2 | |
| SCHEMBL2083862 | 0.83 | HPGD (0.42) | HPGDPTGS2LTB4R2 | |
| SCHEMBL2085836 | 0.82 | HPGD (0.43) | HPGDPTGS2LTB4R2 | |
| SCHEMBL2084566 | 0.82 | NAMPT (0.44) | CYP4F2CYP4A11MMEL1NAMPT | |
| SCHEMBL2083875 | 0.80 | SENP1 (0.42) | CYP4F2CYP4A11HPGDMMEL1CYP4Z1 | |
| SCHEMBL68850 | 0.79 | RAB9A (0.38) | HPGDEPHX2PPARGPPARA | |
| SCHEMBL2085088 | 0.79 | PTGS2 (0.49) | PTGS2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863332-B2 | Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-04 | — | — | US | disclosed |
| EP-1781297-B1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-10-15 | — | — | EP | disclosed |
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-13 | — | — | US | disclosed |
| EP-1781297-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018326-A1 | NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213336-A1 | Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | CYP4F2 601/4885CYP4A11 258/4885HPGD 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.